Cooley advised Secura Bio on intellectual property diligence matters surrounding its acquisition of global rights to Farydak from Novartis. Farydak is a prescription medication used to treat patients who have received prior treatment for multiple myeloma, a cancer that forms malignant plasma cells in the bone marrow.
“We are very pleased to acquire worldwide rights to Farydak as we execute our plan to aggressively build a meaningful, worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio. “Farydak will be a critical cornerstone of our strategy, as it offers a potentially valuable and high-growth treatment option for physicians in their therapeutic regimen for multiple myeloma patients when combined with a variety of other multiple myeloma therapies.”